Allison Bratzel
Stock Analyst at Piper Sandler
(4.92)
# 205
Out of 4,673 analysts
260
Total ratings
63%
Success rate
39.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $82 → $88 | $66.70 | +31.93% | 7 | Aug 19, 2026 | |
| CDXS Codexis | Maintained: Buy | $9 → $8 | $1.67 | +379.04% | 12 | Aug 17, 2026 | |
| INCY Incyte | Maintained: Buy | $110 → $130 | $127.81 | +1.71% | 13 | Aug 17, 2026 | |
| IONS Ionis Pharmaceuticals | Maintained: Buy | $100 → $94 | $59.74 | +57.35% | 14 | Aug 17, 2026 | |
| RIGL Rigel Pharmaceuticals | Maintained: Hold | $40 → $49 | $45.89 | +6.78% | 10 | Aug 17, 2026 | |
| TVTX Travere Therapeutics | Maintained: Buy | $49 → $68 | $65.71 | +3.49% | 21 | Aug 17, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintained: Buy | $68 | $25.83 | +163.26% | 7 | Aug 17, 2026 | |
| AKBA Akebia Therapeutics | Maintained: Buy | $4 | $0.9066 | +341.21% | 18 | Aug 17, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $16 → $15 | $3.89 | +285.60% | 9 | Aug 17, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,075 → $1,215 | $1,039.78 | +16.85% | 34 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $55 | $36.73 | +49.74% | 9 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $14.34 | +109.21% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $2.04 | +96.08% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $0.6422 | +55.71% | 10 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $5.30 | +126.42% | 6 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $13.85 | +116.61% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $14.77 | -5.21% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $11.32 | +6.01% | 7 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $165 → $175 | $114.95 | +52.24% | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $26 → $4 | $1.78 | +124.72% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 → $56 | $26.05 | +114.97% | 5 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $51 → $58 | $56.50 | +2.65% | 13 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3 → $0.5 | $0.0001 | +499,900.00% | 5 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22 | $36.30 | n/a | 6 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $8 → $20 | $9.30 | n/a | 6 | Mar 14, 2024 |
BioMarin Pharmaceutical
Aug 19, 2026
Maintained: Buy
Price Target: $82 → $88
Current: $66.70
Upside: +31.93%
Codexis
Aug 17, 2026
Maintained: Buy
Price Target: $9 → $8
Current: $1.67
Upside: +379.04%
Incyte
Aug 17, 2026
Maintained: Buy
Price Target: $110 → $130
Current: $127.81
Upside: +1.71%
Ionis Pharmaceuticals
Aug 17, 2026
Maintained: Buy
Price Target: $100 → $94
Current: $59.74
Upside: +57.35%
Rigel Pharmaceuticals
Aug 17, 2026
Maintained: Hold
Price Target: $40 → $49
Current: $45.89
Upside: +6.78%
Travere Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $49 → $68
Current: $65.71
Upside: +3.49%
Ultragenyx Pharmaceutical
Aug 17, 2026
Maintained: Buy
Price Target: $68
Current: $25.83
Upside: +163.26%
Akebia Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $4
Current: $0.9066
Upside: +341.21%
Ardelyx
Aug 17, 2026
Maintained: Buy
Price Target: $16 → $15
Current: $3.89
Upside: +285.60%
argenx SE
Aug 17, 2026
Maintained: Buy
Price Target: $1,075 → $1,215
Current: $1,039.78
Upside: +16.85%
Aug 17, 2026
Maintained: Buy
Price Target: $52 → $55
Current: $36.73
Upside: +49.74%
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $14.34
Upside: +109.21%
Aug 17, 2026
Maintained: Buy
Price Target: $4
Current: $2.04
Upside: +96.08%
Aug 17, 2026
Maintained: Hold
Price Target: $1
Current: $0.6422
Upside: +55.71%
Aug 17, 2026
Maintained: Buy
Price Target: $12
Current: $5.30
Upside: +126.42%
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $13.85
Upside: +116.61%
Aug 7, 2026
Maintained: Buy
Price Target: $14
Current: $14.77
Upside: -5.21%
Aug 7, 2026
Maintained: Buy
Price Target: $12
Current: $11.32
Upside: +6.01%
Jul 9, 2026
Rated: Buy
Price Target: $165 → $175
Current: $114.95
Upside: +52.24%
May 8, 2026
Downgraded: Hold
Price Target: $26 → $4
Current: $1.78
Upside: +124.72%
Mar 20, 2026
Maintained: Buy
Price Target: $42 → $56
Current: $26.05
Upside: +114.97%
Mar 4, 2026
Maintained: Buy
Price Target: $51 → $58
Current: $56.50
Upside: +2.65%
Jan 23, 2026
Downgraded: Hold
Price Target: $3 → $0.5
Current: $0.0001
Upside: +499,900.00%
Jul 18, 2024
Maintained: Buy
Price Target: $22
Current: $36.30
Upside: n/a
Mar 14, 2024
Upgraded: Buy
Price Target: $8 → $20
Current: $9.30
Upside: n/a